PD-L1 Expression in Medullary Thyroid Carcinoma and Its Association with Clinicopathological Findings

Creative Commons License

Kemal Y., Çalışkan S., GÜN S., Kefeli M.

TURKISH JOURNAL OF PATHOLOGY, vol.38, no.2, pp.1-8, 2022 (ESCI) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.5146/tjpath.2021.01558
  • Journal Name: TURKISH JOURNAL OF PATHOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1-8
  • Keywords: Medullary thyroid carcinoma, Immunotherapy, Programmed death-ligand 1 (PD-L1), Clinicopathological characteristics, LIGAND 1 EXPRESSION, PROGNOSTIC-FACTORS, CANCER, OVEREXPRESSION
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Objective: Medullary thyroid carcinoma (MTC) is a rare tumor originating from parafollicular C cells. It has more aggressive biologic behavior than differentiated thyroid carcinomas, and it is insensitive to treatment with radioactive iodine. Vandetanib and cabozantinib are the newly approved tyrosine kinase inhibitors in advanced stages, but novel effective systemic therapeutics could be crucial and needed for the clinical management of these patients. We aimed to evaluate the Programmed death-ligand 1 (PD-L1) expression, which is a novel immunotherapy target, in our MTC cohort, and determine whether it has an association with clinical and pathological features.